Overview

Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis

Status:
Completed
Trial end date:
2019-05-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate safety and tolerability of VX-121 in healthy subjects and in subjects with cystic fibrosis (CF).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Treatments:
Ivacaftor